Form 4: Talwalkar Sells iRhythm Shares Under 10b5-1 Plan

Abhijit Talwalkar, a director at iRhythm Technologies, sold shares of IRTC common stock on August 11, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Abhijit Talwalkar, a director of iRhythm Technologies, executed multiple transactions involving IRTC common stock on August 11, 2025.
• 5,312 shares were acquired through the exercise of employee stock options at a price of $10.71 per share.
• 3,183 shares were sold at a weighted average price of $157.5723, with prices ranging from $157.2350 to $158.1800.
• 2,129 shares were sold at a weighted average price of $158.6792, with prices ranging from $158.3100 to $159.0000.
• Following these transactions, Talwalkar directly owns 20,299 shares of iRhythm Technologies common stock.
• Talwalkar also holds options to purchase 15,936 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral. The filing represents routine transactions under a pre-existing plan. There is no clear positive or negative sentiment implied.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned in advance and not based on insider information.
• Exercise of stock options indicates confidence in the company's future.

Negatives

• Sale of shares by a director could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The filing does not explicitly mention risks.

Future Outlook

The filing does not contain explicit forward-looking statements, but the continued operation of the 10b5-1 trading plan suggests ongoing, pre-planned transactions.

Management Comments

• Mr. Talwalkar undertakes to provide upon request of the SEC staff, iRhythm Technologies, Inc. or any security holder of iRhythm Technologies, Inc., full information regarding the numbers of shares sold at each price within the range.

Industry Context

This filing reflects routine transactions by a company insider and doesn't necessarily indicate specific industry trends. However, insider transactions are always closely watched by investors for signals about company performance and valuation.

Comparison to Industry Standards

• It is difficult to compare this specific filing to industry standards as it represents an individual's transaction rather than company-wide performance.
• However, the use of 10b5-1 trading plans is a common practice among corporate insiders to avoid accusations of insider trading, aligning with standard corporate governance practices.
• Comparable companies in the medical device space, such as Medtronic or Boston Scientific, also see regular insider transactions, but the significance varies based on the individual and the size of the transaction relative to their holdings.

Stakeholder Impact

• Shareholders: The sale of shares could have a minor negative impact on investor sentiment, but the pre-planned nature of the transactions mitigates this concern.
• Employees: No direct impact on employees.
• Customers: No direct impact on customers.
• Suppliers: No direct impact on suppliers.
• Creditors: No direct impact on creditors.

Next Steps

• Monitor future Form 4 filings by Mr. Talwalkar to observe any changes in his trading activity.
• Review overall insider transaction trends for iRhythm Technologies to gauge sentiment among company leadership.

Key Dates

Recommendation

The transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the director's outlook on the company. Therefore, a hold recommendation is appropriate.

Keywords

iRhythm Technologies, IRTC, Abhijit Talwalkar, Form 4, stock sale, Rule 10b5-1 plan, insider trading